In October, ASBM recorded the latest entry in its ongoing continuing education (CE) series in partnership with the Ohio State University College of Pharmacy. This course module, entitled “Patient Perspectives on Biosimilars”, represents part 6 of the 7-part series covering a wide range of biosimilar policy issues.

In this module, participants will hear different perspectives from the patient community regarding biosimilars and how they are made available to patients. ASBM Steering Committee Member Andrew Spiegel will share his perspective as the head of two international patient organizations (the Global Colon Cancer Association and World Patients Alliance) as well as sharing the perspectives of several other patient advocacy experts from the U.S., Europe, Canada, and Australia.

Upon completion, participants will be able to:

  1. Identify key benefits and challenges that biosimilars create for patients
  2. Describe concerns that patients have under different biosimilar access scenarios.
  3. Compare and contrast the roles of the physician and patient in treatment decisions in the different biosimilar markets examined.
  4. Discuss tactics the patient community have used to improve access to biosimilars and control over treatment.=

The final entry in the CE series, entitled “PBM and Payer Practices” and featuring Immediate Past ASBM Chair Madelaine Feldman, MD FACR; will be available in the coming weeks.

View all the available OSU College of Pharmacy CE courses here. (registration required).

View the course outline here.

View a promotional trailer for the CE series here.